Literature DB >> 24261904

Explorations of substituted urea functionality for the discovery of new activators of the heme-regulated inhibitor kinase.

Ting Chen1, Khuloud Takrouri, Sung Hee-Hwang, Sandeep Rana, Revital Yefidoff-Freedman, Jose Halperin, Amarnath Natarajan, Christophe Morisseau, Bruce Hammock, Michael Chorev, Bertal H Aktas.   

Abstract

Heme-regulated inhibitor kinase (HRI), a eukaryotic translation initiation factor 2 alpha (eIF2α) kinase, plays critical roles in cell proliferation, differentiation, and adaptation to cytoplasmic stress. HRI is also a critical modifier of hemoglobin disorders such as β-thalassemia. We previously identified N,N'-diarylureas as potent activators of HRI suitable for studying the biology of this important kinase. To expand the repertoire of chemotypes that activate HRI, we screened a ∼1900 member N,N'-disubstituted urea library in the surrogate eIF2α phosphorylation assay, identifying N-aryl,N'-cyclohexylphenoxyurea as a promising scaffold. We validated hit compounds as a bona fide HRI activators in secondary assays and explored the contributions of substitutions on the N-aryl and N'-cyclohexylphenoxy groups to their activity by studying focused libraries of complementing analogues. We tested these N-aryl,N'-cyclohexylphenoxyureas in the surrogate eIF2α phosphorylation and cell proliferation assays, demonstrating significantly improved bioactivities and specificities. We consider these compounds to represent lead candidates for the development of potent and specific HRI activators.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24261904      PMCID: PMC3938169          DOI: 10.1021/jm400793v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  34 in total

Review 1.  When translation meets metabolism: multiple links to diabetes.

Authors:  Yuguang Shi; Simeon I Taylor; Seng-Lai Tan; Nahum Sonenberg
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

2.  Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation.

Authors:  T Krishnamoorthy; G D Pavitt; F Zhang; T E Dever; A G Hinnebusch
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Regulation of guanine nucleotide exchange through phosphorylation of eukaryotic initiation factor eIF2alpha. Role of the alpha- and delta-subunits of eiF2b.

Authors:  S R Kimball; J R Fabian; G D Pavitt; A G Hinnebusch; L S Jefferson
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

4.  Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole.

Authors:  H Aktas; R Flückiger; J A Acosta; J M Savage; S S Palakurthi; J A Halperin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

5.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1.

Authors:  H Aktas; H Cai; G M Cooper
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

6.  Modulation of tRNA(iMet), eIF-2, and eIF-2B expression shows that GCN4 translation is inversely coupled to the level of eIF-2.GTP.Met-tRNA(iMet) ternary complexes.

Authors:  T E Dever; W Yang; S Aström; A S Byström; A G Hinnebusch
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

7.  Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid.

Authors:  S S Palakurthi; R Flückiger; H Aktas; A K Changolkar; A Shahsafaei; S Harneit; E Kilic; J A Halperin
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

8.  Perk is essential for translational regulation and cell survival during the unfolded protein response.

Authors:  H P Harding; Y Zhang; A Bertolotti; H Zeng; D Ron
Journal:  Mol Cell       Date:  2000-05       Impact factor: 17.970

9.  Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene.

Authors:  Anna Biason-Lauber; Mariarosaria Lang-Muritano; Tindara Vaccaro; Eugen J Schoenle
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

10.  Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells.

Authors:  O Donzé; R Jagus; A E Koromilas; J W Hershey; N Sonenberg
Journal:  EMBO J       Date:  1995-08-01       Impact factor: 11.598

View more
  12 in total

1.  The eIF2α Kinase Heme-Regulated Inhibitor Protects the Host from Infection by Regulating Intracellular Pathogen Trafficking.

Authors:  Wael Bahnan; Justin C Boucher; Petoria Gayle; Niraj Shrestha; Mark Rosen; Bertal Aktas; Becky Adkins; Arba Ager; Wasif N Khan; Kurt Schesser
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

2.  Development of 1-((1,4-trans)-4-Aryloxycyclohexyl)-3-arylurea Activators of Heme-Regulated Inhibitor as Selective Activators of the Eukaryotic Initiation Factor 2 Alpha (eIF2α) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response.

Authors:  Revital Yefidoff-Freedman; Jing Fan; Lu Yan; Qingwen Zhang; Guillermo Rodrigo Reis Dos Santos; Sandeep Rana; Jacob I Contreras; Rupam Sahoo; Debin Wan; Jun Young; Karina Luiza Dias Teixeira; Christophe Morisseau; Jose Halperin; Bruce Hammock; Amarnath Natarajan; Peimin Wang; Michael Chorev; Bertal H Aktas
Journal:  J Med Chem       Date:  2017-06-19       Impact factor: 7.446

3.  Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

Authors:  Mohammad Zarei; Eugènia Pujol; Tania Quesada-López; Francesc Villarroya; Emma Barroso; Santiago Vázquez; Javier Pizarro-Delgado; Xavier Palomer; Manuel Vázquez-Carrera
Journal:  Br J Pharmacol       Date:  2019-05-23       Impact factor: 8.739

Review 4.  Therapeutic Opportunities in Eukaryotic Translation.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

5.  The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma.

Authors:  Nicholas Burwick; Michael Y Zhang; Pilar de la Puente; Abdel Kareem Azab; Teresa S Hyun; Melisa Ruiz-Gutierrez; Marilyn Sanchez-Bonilla; Tomoka Nakamura; Jeffrey J Delrow; Vivian L MacKay; Akiko Shimamura
Journal:  Leuk Res       Date:  2017-01-12       Impact factor: 3.156

6.  Perspective: Modulating the integrated stress response to slow aging and ameliorate age-related pathology.

Authors:  Maxime J Derisbourg; Matías D Hartman; Martin S Denzel
Journal:  Nat Aging       Date:  2021-09-13

Review 7.  The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.

Authors:  Nicholas Burwick; Bertal H Aktas
Journal:  Expert Opin Ther Targets       Date:  2017-10-30       Impact factor: 6.902

8.  ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.

Authors:  C Leah B Kline; A Pieter J Van den Heuvel; Joshua E Allen; Varun V Prabhu; David T Dicker; Wafik S El-Deiry
Journal:  Sci Signal       Date:  2016-02-16       Impact factor: 8.192

9.  Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.

Authors:  Sandeep Rana; Yogesh A Sonawane; Margaret A Taylor; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2018-10-15       Impact factor: 2.823

10.  Depletion of eIF2·GTP·Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.

Authors:  Bertal H Aktas; Paula Bordelois; Selen Peker; Sophia Merajver; Jose A Halperin
Journal:  Oncotarget       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.